Here Are Friday's Biggest Analyst Calls: Nvidia, Apple, Netflix, JPMorgan, Affirm, UnitedHealth, WeRide & More

Why It Matters

These rating changes signal shifting confidence across technology, semiconductor exposure, and healthcare, guiding institutional capital flows. The mix of upgrades, downgrades, and new initiations highlights where analysts see growth catalysts and risk in the current macro environment.

Key Takeaways

• Apple remains a “high‑quality compounder” despite YTD underperformance
• Nvidia reaffirmed Outperform with $265 target, citing AI platform dominance
• Mizuho cuts NXP to Sell, citing auto sector headwinds
• Morgan Stanley flags UnitedHealth as top pick amid favorable Medicare Advantage rates
• Multiple biotech initiations signal growing specialty pharma investor interest

Pulse Analysis

Analysts are sharpening their focus on AI‑driven tech giants as the sector continues to outpace broader markets. Bank of America’s reaffirmation of Nvidia’s Outperform rating, backed by a $265 price target, reflects confidence in the company’s expanding AI platform and its projected $1 trillion‑plus revenue stream through 2027. Meanwhile, Apple’s buy rating underscores its resilient services revenue and a robust product pipeline, even as the stock lags the S&P 500 year‑to‑date. In contrast, semiconductor exposure to the auto industry is under scrutiny; Mizuho’s downgrade of NXP to Sell highlights concerns over a softer automotive outlook and geopolitical headwinds, prompting investors to reassess exposure to auto‑centric chipmakers.

The financial services and healthcare segments also saw notable analyst moves. Morgan Stanley’s elevation of UnitedHealth to a top pick is anchored in expectations of favorable Medicare Advantage rate adjustments, which could drive a series of clean earnings quarters. Similarly, JPMorgan’s inclusion on Bank of America’s US‑1 list signals strong confidence in its diversified banking model, while the firm’s removal of Goldman Sachs reflects a nuanced view of investment banking volatility. In the consumer space, Netflix retained its buy rating after a solid first‑quarter performance, reinforcing its strategy of leveraging technology to enhance content monetization and user engagement.

Biotech and specialty‑pharma stocks attracted fresh enthusiasm, with multiple buy initiations from Goldman Sachs, Rothschild & Co Redburn and UBS. Companies like Corvus, Repligen and Amneal are positioned as leaders in niche therapeutic areas such as atopic dermatitis and continuous bioprocessing, offering investors differentiated growth pathways amid broader market uncertainty. These initiations suggest a strategic shift toward high‑margin, innovation‑driven healthcare assets, as analysts seek opportunities that can deliver outsized returns despite macro‑level headwinds. The convergence of tech optimism, cautious semiconductor exposure, and renewed biotech interest paints a complex but opportunity‑rich landscape for investors navigating 2026’s market dynamics.